MD1003

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis2
10Charcot-Marie-Tooth disease2
13Multiple sclerosis14
IDDisease name (Link within this page)Number of trials
14Chronic inflammatory demyelinating polyneuropathy1
20Adrenoleukodystrophy2

2. Amyotrophic lateral sclerosis


Clinical trials : 786Drugs : 550 - (DrugBank : 182) / Drug target genes : 170 - Drug target pathways : 232 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

10. Charcot-Marie-Tooth disease


Clinical trials : 45Drugs : 34 - (DrugBank : 10) / Drug target genes : 12 - Drug target pathways : 22 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis


Clinical trials : 3,685Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

14. Chronic inflammatory demyelinating polyneuropathy


Clinical trials : 223Drugs : 119 - (DrugBank : 28) / Drug target genes : 11 - Drug target pathways : 22 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

20. Adrenoleukodystrophy


Clinical trials : 68Drugs : 74 - (DrugBank : 32) / Drug target genes : 25 - Drug target pathways : 131 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries